ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 879

Serological Biomarkers Of Specific Mode Of Action For Early Identification Of Rheumatoid Arthritis Patients Who Respond To Anti-IL6 Or Anti-TNF Treatment

Anne C. Bay-Jensen1, Natasja Stæhr Gudman2, Anne Sofie Siebuhr1, Claus Christiansen3 and Morten Asser Karsdal2, 1Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Collagen, Inflammation, rheumatic disease and treatment options

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized debilitating joint destruction, if not treated aggressively in the patient in most need of treatment.  Personalized health care is needed in RA, as response rates are low compared to the potential side effects and cost of treatment. Anti-IL6 and anti-TNF treatments are approved for treatment of RA patients, however with varying response rates. A unique class of serological biomarkers, which are measures of extracellular matrix turnover, also called protein fingerprint, may describe specific disease mode of actions. We investigated whether early measurement after treatment initiation could identify patients that would respond to either anti-IL6 or anti-TNF treatment. 

Methods: Following tissue-specific biomarkers were measured in 800 RA patients treated with either methotrexate, tocilizumab, infliximab, entercept or adalimumab; VICM (citrullinated and MMP-degraded vimentin), C1M (MMP-degraded type I collagen), C3M (MMP-degraded type III collagen), CRPM (MMP-degraded CRP), C2M (MMP-degraded type II collagen), CTx (cathepsin K degraded type I collagen), osteocalcin (bone formation), and CRP (acute phase reactant). The baseline levels and changes in the biomarkers were investigated was investigated for each of the treatment groups. Logistic regression and classification and regression tree analysis were used to assess whether the markers alone or together could predict treatment response evaluated by DAS28 changes. Data was corrected for multiplicity.

Results: Methothraxate had a small effect on CRP, but not on any of the other markers. Tocilizumab significantly suppressed (p<0.0001) the level the connective tissue markers MMP3, VICM, C1M, C2M, C3M, CRPM and significantly increased (p<0.05) the level of the bone markers CTx and ostoecalcin. In contrast, cartilage degradation measured by C2M, was not inhibited anti-TNF treatment. A simple combination of the biomarkers (C1M, C3M, C2M, osteocalcin and CRPM) was able to double the DAS28 response rate of tocilizumab 27 to 54%. When including the change from baseline to 4 or 16 weeks in cartilage degradation or bone formation the rate was increased to 64%. Similar segregation could be reached for the anti-TNF group, however with a different set of markers; C1M, C3M, VICM and CRPM.

Conclusion: Distinct mode of action profiles were identified for each of the different treatment groups by measurement of the unique protein fingerprint markers. This may assist in identification of the patients, in any inflammatory disease, who respond most optimally to given interventions, with fewer AEs, and thus provide a stronger risk/benefit/cost value proposition to patients and payers.


Disclosure:

A. C. Bay-Jensen,

Nordic Bioscnce,

3;

N. S. Gudman,

Nordic Bioscience,

3;

A. S. Siebuhr,

Nordic Bisocience,

3;

C. Christiansen,

Nordic Bioscience Diagnostic,

1,

Nordic Bioscience Diagnostic,

6;

M. A. Karsdal,

Nordic Bioscience ,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serological-biomarkers-of-specific-mode-of-action-for-early-identification-of-rheumatoid-arthritis-patients-who-respond-to-anti-il6-or-anti-tnf-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology